© 2025 Edison Investment Research
Aktien»Nachrichten»IRLAB THERAPEUTICS AKTIE»IRLAB Therapeutics (STO: IRLAB-A) announces loan term extension and new shareholder loan
Frankfurt
21.02.25
08:19 Uhr
1,260 Euro
-0,035
-2,70 %
-2,70 %
IRLAB Therapeutics (STO: IRLAB-A) announces loan term extension and new shareholder loan
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | IRLAB Therapeutics - EMA alignment on mesdopetam Phase III plans | IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European Medicines Agency (EMA) is aligned with the company... ► Artikel lesen | |
| Do | IRLAB Therapeutics: IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam | GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 February, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company... ► Artikel lesen | |
| Di | IRLAB Therapeutics - Financing improves operational flexibility | IRLAB Therapeutics has renegotiated its loan terms with Fenja Capital, allowing it to extend the duration of its SEK55m loan from 22 May 2025, potentially to 30 June 2026. The loan value may also be... ► Artikel lesen | |
| Di | IRLAB Therapeutics (STO: IRLAB-A) announces loan term extension and new shareholder loan | IRLAB has renegotiated its loan terms with FENJA Capital, allowing it to extend duration of the SEK55m loan from May 2025 to 31 December 2025 and potentially to 30 June 2026 (for an additional fee of... ► Artikel lesen | |
| Di | IRLAB Therapeutics: IRLAB Strengthens Its Value Creation Capabilities Through Extended And Expanded Debt Financing | GOTHENBURG, SWEDEN / ACCESS Newswire / February 17, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)/ IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen,
bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen
Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu
verstehen sein kann.
